.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,855,175

« Back to Dashboard

Details for Patent: 7,855,175

Title:Peptides that bind to the erythropoietin receptor
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
Inventor(s): Holmes; Christopher P. (Saratoga, CA), Yin; Qun (Palo Alto, CA), Lalonde; Guy (Woodside, CA), Schatz; Peter J. (Cupertino, CA), Tumelty; David (San Diego, CA), Balu; Palani (Cupertino, CA), Zemede; Genet (San Jose, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Filing Date:Jul 11, 2008
Application Number:12/171,610
Claims:1. A compound that binds to and activates the erythropoietin receptor (EPO-R), which compound comprises: (a) a first peptide monomer and a second peptide monomer, wherein the first and second peptide monomers each comprises the amino acid sequence (AcG)GLYACHMGPIT(1-nal)VCQPLR (SEQ ID NO:14); and (b) at least one lysine linker moiety covalently bonding the C-terminus of said first peptide monomer and the C-terminus of said second peptide monomer to a spacer moiety, wherein the spacer moiety is attached via an amide linkage to a carbonyl carbon of said lysine linker moiety and has the formula: ##STR00085## wherein R.sub.2 is selected from the group consisting of CO and COO, and PEG is a poly(ethylene glycol) moiety comprising a linear, unbranched poly(ethylene glycol) having a molecular weight of about 10,000 to about 60,000 Daltons.

2. The compound of claim 1, wherein the C-terminus of the amino acid sequence additionally comprises (MeG).

3. The compound of claim 2, wherein the amino acid sequence is: (AcG)GLYACHMGPIT(1-nal)VCQPLR(MeG) (SEQ ID NO:3).

4. The compound of claim 1, wherein the PEG is 10,000 to 60,000 Daltons.

5. The compound of claim 1, wherein the PEG is 20,000 to 40,000 Daltons.

6. A method for treating a patient having a disorder characterized by a deficiency of erythropoietin or a low or defective red blood cell population, which method comprises administering to the patient a therapeutically effective amount of a compound that binds to and activates the erythropoietin receptor (EPO-R), which compound comprises: (a) a first peptide monomer and a second peptide monomer, wherein the first and second peptide monomers each comprises the amino acid sequence (AcG)GLYACHMGPIT(1-nal)VCQPLR (SEQ ID NO:14); and (b) at least one lysine linker moiety covalently bonding the C-terminus of said first peptide monomer and the C-terminus of said second peptide monomer to a spacer moiety, wherein the spacer moiety is attached via an amide linkage to a carbonyl carbon of said lysine linker moiety and has the formula: ##STR00086## wherein R.sub.2 is selected from the group consisting of CO and COO, and PEG is a poly(ethylene glycol) moiety comprising a linear, unbranched poly(ethylene glycol) having a molecular weight of about 10,000 to about 60,000 Daltons.

7. The method according to claim 6, wherein the disorder is selected from the group consisting of end stage renal failure or dialysis, beta-thalassemaia, cystic fibrosis, spinal cord injury, acute blood loss, aging and neoplastic disease states accompanied by abnormal erythropoiesis.

8. The method according to claim 6, wherein the disorder is anemia.

9. A method according to claim 8, wherein the anemia is selected from the group consisting of anemia associated with AIDS, auto immune disease or a malignancy; early anemia of prematurity; anemia associated with chronic inflammatory disease; and anemia associated with chronic kidney disease.

10. The method according to claim 6, wherein the PEG has a molecular weight of about 20,000 Daltons.

11. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

12. The pharmaceutical composition according to claim 11, wherein each PEG has a molecular weight of about 20,000 Daltons.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc